Form 4: Century Therapeutics SVP Sells Shares for Tax Obligations

SVP of Finance & Operations Douglas Carr sold 1,654 shares of Century Therapeutics to cover tax withholding obligations.

Summary

• Douglas Carr, SVP of Finance & Operations at Century Therapeutics, Inc. (IPSC), sold 1,654 shares of common stock.
• The transaction occurred on June 12, 2026, at a price of $2.232 per share.
• Following the transaction, the reporting person retains beneficial ownership of 505,094 shares.
• The sale was executed automatically to satisfy tax withholding requirements related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory, non-discretionary action to satisfy tax obligations rather than a strategic divestment.

Positives

• The sale was non-discretionary and strictly for tax compliance purposes, indicating no change in long-term investment sentiment.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• General market volatility affecting the share price of biotechnology companies.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for corporate executives in the biotech sector to manage tax liabilities upon the vesting of equity compensation, and they generally do not signal a change in management's outlook on the company's performance.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation practices across the biotechnology industry.
• Automatic tax-related sales are common among peers such as CRISPR Therapeutics or Editas Medicine when restricted stock units vest.

Stakeholder Impact

• Minimal impact on shareholders as the sale was automatic and limited in volume.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Century Therapeutics, IPSC, Insider Trading, Form 4, Biotechnology, Tax Withholding